Company profile for KBP Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

KBP Biosciences is a global clinical stage biopharmaceutical company focused on the development of an innovative pipeline of new chemical entities with known mechanisms of action targeting underserved patient populationsin organ protection and infectious diseases. KBP utilizes an integrated discovery and development platform that enables the Company to efficiently bring new therapies from bench to patients around the world. ...
KBP Biosciences is a global clinical stage biopharmaceutical company focused on the development of an innovative pipeline of new chemical entities with known mechanisms of action targeting underserved patient populationsin organ protection and infectious diseases. KBP utilizes an integrated discovery and development platform that enables the Company to efficiently bring new therapies from bench to patients around the world. Our lead product candidate, KBP-5074, is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a potentially best-in-class safety and efficacy profile.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Princeton, New Jersey 116 Village Blvd., Suite 210 Princeton, NJ 08540
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/novo-nordisk-versus-kbp-13b-deal-table-fraud-legal-battlefield

FIERCE BIOTECH
02 Oct 2025

https://www.fiercebiotech.com/biotech/novo-nordisk-sue-kbp-biosciences-alleged-fraudulent-claims-kidney-disease-drugs

FIERCE BIOTECH
19 Feb 2025

https://www.biopharmadive.com/news/novo-ocedurenone-kbp-terminate-study-charge-blood-pressure/719947/

Jonathan Gardner BIOPHARMADIVE
27 Jun 2024

https://www.globenewswire.com//news-release/2023/10/16/2760508/0/en/Novo-Nordisk-to-acquire-ocedurenone-for-uncontrolled-hypertension-from-KBP-Biosciences.html

GLOBENEWSWIRE
16 Oct 2023

https://www.prnewswire.com/news-releases/ocedurenone-kbp-5074-featured-at-asn-kidney-week-ocedurenone-is-a-potential-new-treatment-option-for-patients-with-uncontrolled-or-resistant-hypertension-and-advanced-ckd-301715194.html

PR NEWSWIRE
06 Jan 2023

https://www.globenewswire.com/news-release/2021/06/16/2248139/0/en/KBP-Biosciences-Announces-A-Greater-Than-10-mm-Hg-Systolic-Blood-Pressure-Reduction-in-The-BLOCK-CKD-Phase-2b-Study-of-KBP-5074-in-Advanced-Chronic-Kidney-Disease-Patients-with-Unc.html

GLOBENEWSWIRE
16 Jun 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty